Xuyi Liu

Xuyi Liu

Auto-generated profile, based on publicly available information

Xuyi Liu

Research Center of Nano Technology and Application Engineering, The First Dongguan Affiliated Hospital, School of Pharmacy, Guangdong Medical University, Dongguan, 523808, People’s Republic of China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2025 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
GJGuanming Jiang
Guanming Jiang
XLXuyi Liu
Xuyi Liu
DZDou Zhang
Dou Zhang
ZDZhenying Diao
Zhenying Diao
XYXiaojun Yang
Xiaojun Yang
JZJianping Zhou
Jianping Zhou
Purpose: Osimertinib, established as the frontline treatment for advanced non-small cell lung cancer (NSCLC), can effectively prolong progression-free survival. However, it faces the problem of reduced treatment persistence due to acquired drug resistance. Meanwhile, tumor hypoxia is also a key driver of drug resistance. This study proposes a hybrid protein oxygen nanocarrier combined with osimertinib and ginsenoside Rg3 to address the drug resistance issue of NSCLC through multiple mechanisms. Methods: A hybrid protein-oxygen multifunctional nanoplatform (OG@HPO) was engineered by co-encapsulating OSI and GRg3 within oxygen-rich protein matrices. Initial confirmed the synthesis of OG@HPO and characterized its drug/oxygen release. Subsequent in vitro assays verified OG@HPO’s tumoricidal activity and elucidated its mechanistic. Finally, in vivo evaluations validated the nanoplatform’s tumor targeting and anticancer efficacy. Results: Preliminary experiments confirmed successful OG@HPO preparation and validated its drug/oxygen release capacities. In vitro assays demonstrated the potent cytotoxic effects of OG@HPO against H1975 OR cells. In vivo biodistribution studies revealed excellent tumor-targeting of OG@HPO in H1975 OR xenograft mice. Subsequent 18 days therapeutic monitoring showed superior antitumor efficacy accompanied and favorable biosafety profile of OG@HPO. More importantly, in vitro and in vivo studies demonstrated that OG@HPO effectively oxygenate tumor microenvironment, thereby inhibiting hypoxia-driven HIF-1α expression and simultaneously inhibiting the vascular endothelial growth factor (VEGF)/EGFR pathway. Conclusion: OG@HPO represents an innovative multifunctional nanoplatform integrating tumor-targeting, multi-drug delivery, and hypoxia modulation capabilities. By effectively alleviating tumor hypoxia, it achieves multiple inhibition of HIF-1α and EGFR/VEGF pathways. Ultimately, enhances NSCLC sensitivity to osimertinib, thereby reversing acquired resistance. Overall, OG@HPO is regarded as a promising strategy to overcome osimertinib resistance providing a clinically translatable solution.

1 July 2026 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
TYTing Yin
Ting Yin
XLXuyi Liu
Xuyi Liu
JBJinyu Bai
Jinyu Bai
LQLong Qiu
Long Qiu
JHJunjian Hu
Junjian Hu
DCDaxiang Cui
Daxiang Cui
Purpose: Photodynamic therapy (PDT) utilizes photosensitizers to generate reactive oxygen species (ROS) to kill tumors. However, the tumor’s hypoxia and the limitations of a single ROS mechanism severely restrict its efficacy. This study aims to develop a synergistic nano-catalytic system (HMO) based on hollow manganese dioxide (HMnO2) loaded with a novel nitric oxide (NO) donor (Methylene Blue - NO, MB-NO), which overcomes these obstacles through multiple synergistic effects. Methods: Preliminary experiments confirmed the synthesis of HMO. Systematic studies were conducted on the chemodynamic therapy (CDT)/PDT/NO properties of HMO as well as its anti-tumor activity in vivo and in vitro. Finally, the in vivo safety of HMO was evaluated. Results: Preparation by the HMO is 189 nm nano particle size, Zeta potential for −37 ± 1.4 mV, exhibit excellent stability. In vitro experiments showed that the cellular uptake of HMO was time-dependent. In terms of cytotoxicity, the cell survival rate of the HMO group was 65.9%, significantly lower than that of the free HMnO2 (89.1%) and MB-NO (85.1%); after 5 min of 660 nm laser irradiation, the cell survival rate of the HMO group further dropped to 48.5%. In the animal experiments of tumor xenograft models, the tumor inhibition rate of the HMO combined with 660 nm laser irradiation for 5 min group was as high as 81.3%, and it did not cause acute inflammation in the main organs, demonstrating good biological safety. In summary, the HMO nanoparticles exhibit excellent anti-tumor effects. Conclusion: This strategy combines CDT/PDT/gas therapy, enabling the synergistic cascade of NO/ROS/reactive nitrogen oxide species (RNOS) to promote tumor cell apoptosis and inhibit tumor growth, thereby achieving a cascading amplification of therapeutic effects and providing a treatment solution to overcome the inherent limitations of traditional photodynamic therapy.